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Abstract
The immunomodulatory role of 1,25-dihydroxyvitamin D3 is well
known. An association between vitamin D receptor (VDR) gene
BsmI polymorphisms and systemic lupus erythematosus (SLE)
has been reported. To examine the characteristics of VDR gene
BsmI polymorphisms in patients with SLE and the relationship
of polymorphisms to the susceptibility and clinical
manifestations of SLE, VDR genotypings of 101 Thai patients
with SLE and 194 healthy controls were performed based on
polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP). The relationship between VDR
gene BsmI polymorphisms and clinical manifestations of SLE
was evaluated. The distribution of VDR genotyping in patients
with SLE was 1.9% for BB (non-excisable allele homozygote),
21.78% for Bb (heterozygote), and 76.23% for bb (excisable
allele homozygote). The distribution of VDR genotyping in the
control group was 1.03% for BB, 15.98% for Bb, and 82.99%
for bb. There was no statistically significant difference between
the two groups (p = 0.357). The allelic distribution of B and b
was similar within the groups (p  = 0.173). The relationship
between VDR genotype and clinical manifestation or laboratory
profiles of SLE also cannot be statistically demonstrated. In
conclusion, we cannot verify any association between VDR
gene BsmI polymorphism and SLE. A larger study examining
other VDR gene polymorphisms is proposed.
Introduction
The importance of genetic influences on systemic lupus ery-
thematosus (SLE) has been recognized through cumulative
genetic epidemiologic studies. Many population-based stud-
ies have shown associations between the disease and alleles
of immunologically relevant genes, including certain major his-
tocompatibility complex (MHC) loci, Fcγ receptor, and
cytokines [1]. 1,25-dihydroxyvitamin D3 is thought to exert
many of its action through interaction with a specific intracel-
lular receptor. At the molecular level, 1,25-dihydroxyvitamin D3
inhibits the accumulation of mRNA for interleukin (IL)-2, inter-
feron (IFN)-γ, and granulocyte-macrophage colony-stimulating
factor (GM-CSF). At the cellular level, the hormone interferes
with T helper cell (Th) function, reducing Th induction of immu-
noglobulin production by B cells. When given in vivo, 1,25-
dihydroxyvitamin D3 has been particularly effective in preven-
tion of autoimmune diseases such as experimental autoim-
mune encephalitis and murine lupus [2]. It has been
demonstrated that patients with SLE have a lower level of 25
hydroxyvitamin D3 than do healthy controls [3]. In addition,
high-dose 1,25-dihydroxyvitamin D3 and its analog may be
useful therapeutic agents for psoriatic arthritis [4] and rheuma-
toid arthritis [5].
Polymorphism of the vitamin D receptor (VDR) gene was
found to be associated with many diseases, including oste-
oporosis [6], hyperparathyroidism [7], and prostate cancer [8].
An association between VDR gene polymorphism and SLE in
Japanese and Chinese patients has been reported with mixed
results [9-11]. Although Asians are closely related ethnically,
the genetic admixture in Japan or China is different from that
of Thailand. Because a high prevalence and high clinical sever-
ity of SLE are also observed in the Thai population, we exam-
ined the characteristics of VDR gene BsmI polymorphisms in
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a larger cohort of Thai patients with SLE and the relationship
of polymorphisms to the susceptibility and clinical manifesta-
tions of SLE.
Materials and methods
This study was conducted in accordance with the principles
embodied in the Declaration of Helsinki and was approved by
the ethical committees of the Ramathibodi Hospital, Mahidol
University, Bangkok, Thailand. DNA from 101 patients with
SLE was examined. All patients fulfilled the 1982 revised cri-
teria for SLE [12]. All were females older than 15 years of age.
They did not meet criteria for other autoimmune diseases.
DNA from 194 unrelated healthy subjects served as controls.
All healthy subjects were females older than 15 years of age.
VDR genotyping was performed by polymerase chain reac-
tion-restriction fragment length polymorphism (PCR-RFLP).
Genomic DNA was extracted from peripheral white blood cells
using standard phenol-chloroform method. PCR was carried
out in a final reaction volume of 50 µl. Oligonucleotide primers
designed to anneal to exon 7 (primer 1, 5' CAACCAAGACTA-
CAAGTACCGCGTCAGTGA-3') and intron 8 (primer 2, 5'-
AACCAGCGGGAAGAGGTCAAGGG-3') were used to
amplify 825 bp fragment, including the polymorphic BsmI site
in intron 7 of the gene. The following reagents were added to
a 200-µl ultramicrocentrifuge tube: 5 µl of 10 × buffer (100
mM Tris HCl pH 9.0, 500 mM KCl, and 1.0% Triton x-100), 2
µl of MgCl2 (25 mM), 3 µl of deoxynucleotide triphosphate (2
mM each) (Promega, Madison, WI, USA), 0.5 µl of primer 1
(20 µM), 0.5 µl of primer 2 (20 µM), 2.5 units of Taq DNA
polymerase (Promega), 300 ng of template DNA, and water to
a final volume of 50 µl.
The cycling condition was set as follows: one cycle at 95°C for
3 minutes, 30 cycles at 95°C for 30 seconds, 56°C for 30 sec-
onds, and 72°C for 30 seconds. One final cycle of the exten-
sion was performed at 72°C for 10 minutes.
One microliter of the PCR product was digested at 65°C for 1
hour in the final volume of 10 µl with 5 units of restriction
enzyme BsmI (New England Biolabs Inc., Ipswich, MA, USA)
in 1 × buffer. The digested samples were fractionated by elec-
trophoresis in a 1.5% agarose gel. Restriction fragments were
detected by staining with ethidium bromide, and genotypes
were determined by comparing the restriction length polymor-
phism band patterns with a 100 bp DNA ladder run on the
same gel. The presence of the BsmI restriction site generated
175 bp and 650 bp fragments, whereas the absence of this
site yielded an 825 bp fragment.
The genotypes were classified as excisable allele homozygote
(bb), non-excisable allele homozygote (BB), and heterozygote
(Bb).
Statistical analysis
Analyses were performed with Epi Info™ 2002 Results from
patients with SLE and control subjects were compared using
the χ2 test for statistical significance. Hardy-Weinberg equilib-
rium (HWE) was determined by Pearson's χ2 goodness-of-fit
test.
Results
The distribution of VDR genotyping in patients with SLE was
1.9% for BB, 21.78% for Bb, and 76.23% for bb. The distri-
bution of VDR genotyping in the control group was 1.03% for
BB, 15.98% for Bb, and 82.99% for bb. There was no statis-
tically significance difference between the two groups (p =
0.357) (Table 1). The genotype frequencies were consistent
with HWE in patients and controls (χ2 = 0.08, p = 0.77 and χ2
= 0.14, p = 0.71, respectively). The allelic distribution of B and
b was similar within the two groups (p = 0.173) (Table 2). The
relationship between VDR genotype and clinical manifestation
or laboratory profiles of SLE cannot be statistically demon-
strated (Table 3).
Dicussion
Most tissues in the body, including heart, stomach, pancreas,
bone, skin, gonads, and activated T and B lymphocytes, have
the nuclear receptor for 1,25-dihydroxyvitamin D3 (VDR).
Thus, it is not surprising that 1,25-dihydroxyvitamin D3 has a
multitude of biologic effects that are non-calcemic in nature
[13]. Recent research shows that the biologic action of vitamin
D extends well beyond the classic function to include effects
on immunity, muscle and vasculature, reproduction, and the
growth and differentiation of many cell types [14]. 1,25-Dihy-
Table 2
VDR allelic frequency in patients with SLE and healthy controls
Bb
SLE, n = 101 (%) 26 (12.87) 176 (87.12)
Control, n = 194 (%) 35 (9.02) 353 (90.98)
χ2 test = 2.125, p = 0.145. b, excisable allele; B, non-excisable 
allele; SLE, systemic lupus erythematosus; VDR, vitamin D receptor.
Table 1
Distribution of VDR genotyping in patients with SLE and 
healthy controls
VDR genotype
BB Bb bb
SLE, n = 101 (%) 2 (1.9) 22 (21.78) 77 (76.23)
Control, n = 194 (%) 2 (1.03) 31 (15.98) 161 (82.99)
χ2 test = 2.062, p = 0.357. Hardy-Weinberg equilibrium test: χ2 = 
0.08, p = 0.77 in patients and χ2 = 0.14, p = 0.71 in controls. bb = 
excisable allele homozygote; Bb = heterozygote; BB = non-excisable 
allele homozygote; SLE, systemic lupus erythematosus; VDR, vitamin 
D receptor.Available online http://arthritis-research.com/content/8/2/R48
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droxyvitamin D3 directly inhibits synthesis and secretion of IL-
2 [15,16] and IFN-γ [17,18] and also inhibits immunoglobulin
production [19]. Genomic actions of 1,25-dihydroxyvitamin
D3 are mediated through its nuclear receptor (VDR). The VDR
regulates gene transcription by binding to the hexameric core
binding motif in promoter region of target genes, VDR element
(VDRE) [17]. Extensive studies focused on this VDR gene in
various phenotypes have revealed the association between
VDR polymorphism and many non-skeletal diseases [20].
Although SLE has features consistent with Th2-type cytokine
predominance, both Th1 and Th2 cytokine may be involved in
the pathogenesis of SLE [21]. Mononuclear cells of patients
with SLE have defects in IL-2 signal transduction and
decreased production of IFN-γ [22]. IFN-γ, tumor necrosis fac-
tor (TNF)-α, and IL-1 are the most important adhesion mole-
cules inducing cytokine, and they increase in autoimmune
renal disease, particularly in Mrl/lpr-Fas and NZB/W mice
[23].
Recently, VDR gene BsmI polymorphisms have been used as
genetic markers to determine their association with SLE [9-
11]. A Japanese study of 58 patients with SLE found that the
BB genotype might trigger the development of SLE and that
the bb genotype was associated with lupus nephritis [9]. A
Taiwanese study[10] of 47 Chinese patients with SLE also
found an increased distribution of the VDR BB genotype in
SLE but indicated no association between the frequency of
VDR allelic variations and clinical manifestations or laboratory
profiles. In our study, the BB genotype is low in both 194
healthy controls and 101 patients with SLE. However, this is
in accordance with previous findings in the Thai population
[24]. Thailand is geographically situated in an area between
China and India. This genetic admixture may influence the dis-
tribution of VDR gene polymorphism. We cannot demonstrate
Table 3
Relationship between VDR genotype and clinical manifestation or laboratory profiles of SLE
BB % (ratio) n = 2 Bb % (ratio) n = 22 bb % (ratio) n = 77 Total % (ratio)
Malar rash 50 (1/2) 54.54 (12/22) 54.54 (42/77) 54.45 (55/101)
Discoid rash 0 (0/2) 27.27 (6/22) 31.16 (24/77) 29.70 (30/101)
Photosensitivity 50 (1/2) 31.81 (7/22) 38.96 (30/77) 37.62 (38/101)
Oral ulcer 50 (1/2) 31.81 (7/22) 36.36 (28/77) 35.64 (36/101)
Arthritis 100 (2/2) 77.27 (17/22) 70.12 (54/77) 72.27 (73/101)
Serositis 50 (1/2) 18.18 (4/22) 9.09 (7/77) 11.88 (12/101)
- Pericardial effusion 0 (0/2) 13.63 (3/22) 7.79 (6/77) 8.91 (9/101)
- Pleural effusion 50 (1/2) 9.09 (2/22) 6.49 (5/77) 7.92 (8/101)
Renal disorder 50 (1/2) 68.18 (15/22) 64.93 (50/77) 65.34 (66/101)
Neurologic disorder 0 (0/2) 9.09 (2/22) 20.77(16/77) 17.82 (18/101)
- Seizure 0 (0/2) 9.09 (2/22) 15.58 (12/77) 13.86 (14/101)
- Psychosis 0 (0/2) 0 (0/22) 9.09 (7/77) 6.93 (7/101)
Hematologic disorder
- Leukopenia 50 (1/2) 40.90 (9/22) 44.15 (34/77) 43.56 (44/101)
- Thrombocytopenia 0 (0/2) 9.09 (2/22) 18.18 (14/77) 15.84 (16/101)
Immunologic disorder
- Anti-DNA 0 (0/2) 71.42 (15/21) 56.66 (34/60) 60.49 (49/81)
- Anti-Sm 0 (0/2) 57.14 (8/14) 32.60 (15/46) 37.09 (23/62)
ANA 100 (2/2) 100 (22/22) 98.68 (75/76) 99 (99/100)
- Homogenous pattern 50 (1/2) 50 (11/22) 48.68 (37/76) 49 (49/100)
- Rim pattern 0 (0/2) 40.90 (9/22) 44.73 (34/76) 33 (33/100)
- Nucleolar pattern 0 (0/2) 0 (0/22) 3.94 (3/76) 3 (3/100)
- Speckle pattern 50 (1/2) 45.45 (10/22) 59.21 (45/76) 56 (56/100)
ANA = anti-nuclear antibodies; bb = excisable allele homozygote; Bb = heterozygote; BB = non-excisable allele homozygote; SLE, systemic lupus 
erythematosus; Sm = Smith; VDR, vitamin D receptor.Arthritis Research & Therapy    Vol 8 No 2    Sakulpipatsin et al.
Page 4 of 4
(page number not for citation purposes)
any association between VDR gene BsmI polymorphism and
SLE. We further examined the relationship between VDR gen-
otype and the individual clinical manifestation or laboratory
profiles of SLE, which also cannot be statistically demon-
strated.
Conclusion
It was apparent that compared with the genotype distribution
of the VDR gene reported in previous studies [9-11], the gen-
otype frequencies in Thais were different. Because our study
includes a larger number of patients and controls than any pre-
vious study, we conclude that there is no association between
VDR gene BsmI  polymorphisms and SLE, at least in Thai
patients. We propose that other VDR gene polymorphisms be
examined.
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